Sutro Biopharma (STRO) Set to Post Quarterly Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Sutro Biopharma to post earnings of ($1.6637) per share and revenue of $13.61 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The company had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. On average, analysts expect Sutro Biopharma to post ($8.41) EPS for the current fiscal year and ($6.95) EPS for the next fiscal year.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $9.29 on Thursday. The stock has a market capitalization of $154.03 million, a price-to-earnings ratio of -0.78 and a beta of 1.49. The stock’s 50 day moving average price is $15.88 and its two-hundred day moving average price is $22.80. Sutro Biopharma has a 52 week low of $7.15 and a 52 week high of $43.85.

Analysts Set New Price Targets

Several brokerages have recently weighed in on STRO. Mizuho raised shares of Sutro Biopharma to a “strong-buy” rating in a research note on Wednesday, September 16th. Wedbush reissued an “outperform” rating and issued a $60.00 price objective on shares of Sutro Biopharma in a research report on Thursday, October 15th. Wall Street Zen cut shares of Sutro Biopharma from a “sell” rating to a “strong sell” rating in a report on Saturday, September 19th. Weiss Ratings downgraded shares of Sutro Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Finally, Citizens Jmp decreased their target price on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $49.50.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.